Lynn V Doering1, Debra K Moser2, Barbara Riegel3, Sharon McKinley4, Patricia Davidson5, Heather Baker6, Hendrika Meischke7, Kathleen Dracup8. 1. University of California, Los Angeles Los Angeles, CA, United States. Electronic address: ldoering@sonnet.ucla.edu. 2. University of Kentucky, Lexington, CA, United States. 3. University of Pennsylvania, Philadelphia, PA, United States. 4. University of Technology, Sydney, Australia. 5. Curtin University of Technology, Sydney, Australia. 6. University of Auckland, Auckland, New Zealand. 7. University of Washington, Seattle, Washington, United States. 8. University of California, San Francisco, San Francisco, CA, United States.
Abstract
BACKGROUND: Incident anxiety and depression are associated separately with cardiac events and mortality in patients after acute coronary syndromes, but the influence of persistent comorbid depression and anxiety on mortality remains unknown. The purpose of this study was to determine the prevalence of comorbid persistent depressive and anxious symptoms in individuals with ischemic heart disease and to evaluate effects on mortality. METHODS: Prospective, longitudinal cohort design in the context of a randomized trial to decrease patient delay in seeking treatment for ischemic heart symptoms (PROMOTION trial) was used, with twelve-month follow-up of 2325 individuals with stable ischemic heart disease. Participants were assessed on enrollment and at 3 months using the Multiple Adjective Affect Checklist and the Brief Symptom Inventory for depressive and anxious symptoms, respectively. RESULTS: At 3 months, 608 individuals (61.7%) reported persistent symptoms of depression, anxiety, or both. Three hundred seventy-nine (42.5%) and 1056 (45.4%) had persistent anxious and depressive symptoms, respectively. Those with persistent, comorbid symptoms had higher mortality compared to others (p=.029). The combined presence of anxious and depressive symptoms contributed significantly to mortality when compared to symptom-free participants (OR 2.35, 95% CI 1.23-4.47, p=.010). The presence of persistent depressive symptoms only and persistent anxious symptoms only were not associated with death, when other demographic and clinical variables were considered. CONCLUSIONS: Persistent symptoms of anxiety and depression increased substantially the risk of death in patients with ischemic heart disease. Future research into shared and unique pathways and treatments is needed.
RCT Entities:
BACKGROUND: Incident anxiety and depression are associated separately with cardiac events and mortality in patients after acute coronary syndromes, but the influence of persistent comorbid depression and anxiety on mortality remains unknown. The purpose of this study was to determine the prevalence of comorbid persistent depressive and anxious symptoms in individuals with ischemic heart disease and to evaluate effects on mortality. METHODS: Prospective, longitudinal cohort design in the context of a randomized trial to decrease patient delay in seeking treatment for ischemic heart symptoms (PROMOTION trial) was used, with twelve-month follow-up of 2325 individuals with stable ischemic heart disease. Participants were assessed on enrollment and at 3 months using the Multiple Adjective Affect Checklist and the Brief Symptom Inventory for depressive and anxious symptoms, respectively. RESULTS: At 3 months, 608 individuals (61.7%) reported persistent symptoms of depression, anxiety, or both. Three hundred seventy-nine (42.5%) and 1056 (45.4%) had persistent anxious and depressive symptoms, respectively. Those with persistent, comorbid symptoms had higher mortality compared to others (p=.029). The combined presence of anxious and depressive symptoms contributed significantly to mortality when compared to symptom-free participants (OR 2.35, 95% CI 1.23-4.47, p=.010). The presence of persistent depressive symptoms only and persistent anxious symptoms only were not associated with death, when other demographic and clinical variables were considered. CONCLUSIONS: Persistent symptoms of anxiety and depression increased substantially the risk of death in patients with ischemic heart disease. Future research into shared and unique pathways and treatments is needed.
Authors: E J Lenze; J C Rogers; L M Martire; B H Mulsant; B L Rollman; M A Dew; R Schulz; C F Reynolds Journal: Am J Geriatr Psychiatry Date: 2001 Impact factor: 4.105
Authors: Kate M Scott; Peter de Jonge; Jordi Alonso; Maria Carmen Viana; Zhaorui Liu; Siobhan O'Neill; Sergio Aguilar-Gaxiola; Ronny Bruffaerts; Jose Miguel Caldas-de-Almeida; Dan J Stein; Giovanni de Girolamo; Silvia E Florescu; Chiyi Hu; Nezar Ismet Taib; Jean-Pierre Lépine; Daphna Levinson; Herbert Matschinger; Maria Elena Medina-Mora; Marina Piazza; José A Posada-Villa; Hidenori Uda; Bogdan J Wojtyniak; Carmen C W Lim; Ronald C Kessler Journal: Int J Cardiol Date: 2013-08-15 Impact factor: 4.164
Authors: Debra K Moser; Kyoung Suk Lee; Jia-Rong Wu; Gia Mudd-Martin; Tiny Jaarsma; Tsuey-Yuan Huang; Xui-Zhen Fan; Anna Strömberg; Terry A Lennie; Barbara Riegel Journal: Int J Nurs Stud Date: 2014-02-28 Impact factor: 5.837
Authors: Carmela Alcántara; Paul Muntner; Donald Edmondson; Monika M Safford; Nicole Redmond; Lisandro D Colantonio; Karina W Davidson Journal: Circ Cardiovasc Qual Outcomes Date: 2015-03-10
Authors: J W Kasckow; J F Karp; E Whyte; M Butters; C Brown; A Begley; S Bensasi; C F Reynolds Journal: J Psychiatr Res Date: 2013-02-13 Impact factor: 4.791
Authors: Abdullah S Alhurani; Rebecca L Dekker; Mona A Abed; Amani Khalil; Marwa H Al Zaghal; Kyoung Suk Lee; Gia Mudd-Martin; Martha J Biddle; Terry A Lennie; Debra K Moser Journal: Psychosomatics Date: 2014-06-02 Impact factor: 2.386
Authors: Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker Journal: BMC Psychiatry Date: 2014-07-02 Impact factor: 3.630